Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LIPC | P11150 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188069 | 0.91 | CACNA1B (0.51) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2190017 | 0.90 | CACNA1B (0.49) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2191826 | 0.90 | CACNA1B (0.49) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2188437 | 0.87 | CACNA1B (0.49) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2190435 | 0.87 | CACNA1B (0.49) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2189383 | 0.86 | CACNA1B (0.55) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2192610 | 0.86 | CACNA1B (0.55) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2191904 | 0.84 | CACNA1B (0.45) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2189711 | 0.84 | CACNA1B (0.45) | CACNA1BCYP3A4NR1I2CYP2D6CYP2C9 | |
| SCHEMBL2186867 | 0.84 | CACNA1B (0.48) | CACNA1BCYP3A4NR1I2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.